Call Us: 888-488-5750

Join VativoRx at the 109th OHA Annual Meeting & Education Summit

We are thrilled to announce that VativoRx will attend the 109th Ohio Hospital Association (OHA) Annual Meeting & Education Summit, held from June 10-12, 2024, at the Hilton Columbus at Easton. This premier event brings together healthcare leaders to discuss innovations, strategies, and solutions to improve healthcare delivery in Ohio.

As a proud partner of the OHA, VativoRx is dedicated to supporting hospitals and healthcare facilities in maximizing their financial health through innovative rebate management solutions. Our proprietary platform helps capture post-administration drug rebates, providing a significant revenue boost without interfering with existing Purchasing or GPO front-end rebates, or 340B status.

Did you know? Many drug manufacturers offer rebates on medications post-administration that can significantly boost your revenue. These rebates can be captured seamlessly with VativoRx, offering additional income streams to healthcare facilities.

Notable Speakers:

The conference will feature several distinguished speakers, including industry experts and healthcare leaders, who will share insights on current trends and future directions in healthcare.

We invite you to visit us at Booth #36 to learn more about how VativoRx can help your facility unlock hidden revenue opportunities and enhance financial performance. Our team will be available to discuss tailored solutions that fit your specific needs and demonstrate our commitment to supporting the healthcare community.

Don’t miss this opportunity to network with peers, gain valuable knowledge, and discover how VativoRx can contribute to your organization’s success. See you at the 109th OHA Annual Meeting & Education Summit!

For more details about the event, visit the Ohio Hospital Association Annual Meeting page.

Martin Shields / Alamy Stock Photo

Humira – The End of an Era

In January 2023, the first biosimilar version of Humira, which is a widely used injectable drug for inflammatory diseases, was approved, marking the end of AbbVie’s two-decade market exclusivity. Humira is used to treat conditions like rheumatoid arthritis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis, and it works by targeting certain proteins in the immune system.

Read More »

Biosimilars — Similar But Not Identical

You may have never heard of biosimilar drugs and that’s probably because they are not commonly prescribed in the United States even though they have been around for over 20 years. So, what are biosimilar drugs? A biosimilar drug is no different in terms of safety and effectiveness than a biologic product, also known as a reference product, and while highly similar it is not identical.

Read More »

Lower Cost Prescription Drugs from Canada, Is It Legal?

In the early 2000s, the FDA set up guidelines in the Regulatory Procedures Manual (RPM) that permitted prescription drugs to be imported from other countries if the patient met very strict guidelines. Just stating that the patient needed the drug due to cost savings was not a justification to obtain the drug.

Read More »